News

Thinking of Buying Madrigal Pharmaceuticals Stock? Eli Lilly Would Like to Have a Word.

  • Madrigal Pharmaceuticals is the only company with an approved drug for MASH. Eli Lilly's latest clinical trial data shows that its candidate may perform even better.
    06/16/2024

Where Will Madrigal Pharmaceuticals Be in 3 Years?

  • Madrigal Pharmaceuticals currently has undisputed dominance in its main market. There are powerful actors trying to elbow their way in and change that status.
    06/15/2024
Profitability
Dividends
Income Statement
Balance Sheet
Cash Flow Statement
Symbol Frequently Asked Questions

Madrigal Pharmaceuticals, Inc. (MDGL) can hold. Click on Rating Page for detail.

The price of Madrigal Pharmaceuticals, Inc. (MDGL) is 278.515 and it was updated on 2024-06-17 09:00:53.

Currently Madrigal Pharmaceuticals, Inc. (MDGL) is in undervalued.

News
    
News

Madrigal Pharma CEO talks competition in the GLP-1 space and new drug rollouts

  • Bill Sibold, Madrigal Pharma CEO, joins 'Fast Money' to talk GLP-1 drug competition, its liver disease treatment, its Mash drug rollout and more.
    Thu, Jun. 13, 2024

Madrigal Pharmaceuticals: The GLP-1 Threat May Be Overcooked

  • Madrigal Pharmaceuticals, Inc. stock has enjoyed peaks and troughs as it has pursued its path to the approval of NASH drug Rezdiffra. The company's stock was buoyant yesterday, enjoying a 15% gain after Wolfe Research initiated positive coverage. Competition from GLP-1 agonists like Eli Lilly's tirzepatide and Novo Nordisk's semaglutide are expected to pose a threat to Rezdiffra's commercial success.
    Wed, Jun. 12, 2024

Better Biotech Stock: Viking Therapeutics vs. Madrigal Pharmaceuticals

  • Madrigal Pharmaceuticals has a monopoly in its main market -- for the moment. Viking Therapeutics has a good candidate, but it could face powerful competitors.
    Mon, Jun. 10, 2024

Madrigal Pharmaceuticals Announces New Data from the Phase 3 MAESTRO-NASH Study of Rezdiffra™ (resmetirom) Presented at the EASL Congress

  • CONSHOHOCKEN, Pa., June 06, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced results from new analyses of the Phase 3 MAESTRO-NASH trial of Rezdiffra being presented at the EASL Congress, which takes place from June 5-8, 2024 in Milan, Italy.
    Thu, Jun. 06, 2024

Is Madrigal Pharmaceuticals Stock a Buy?

  • Madrigal Pharmaceuticals recently earned an impressive approval from the FDA. The biotech still has work to do to reach its peak potential with this medicine.
    Tue, May. 21, 2024
SEC Filings
SEC Filings
Press Releases
StockPrice Release
More Headlines
News

Amalgamated Bank Raises Stock Holdings in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)

  • Amalgamated Bank boosted its holdings in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Free Report) by 2.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 2,119 shares of the biopharmaceutical company’s stock after purchasing an additional 57 shares during the period. Amalgamated Bank’s holdings in Madrigal Pharmaceuticals were worth $490,000 as of its most recent SEC filing. A number of other institutional investors have also recently bought and sold shares of the business. Tower Research Capital LLC TRC boosted its holdings in shares of Madrigal Pharmaceuticals by 21.7% in the 3rd quarter. Tower Research Capital LLC TRC now owns 2,060 shares of the biopharmaceutical company’s stock worth $301,000 after buying an additional 367 shares during the last quarter. Glenmede Trust Co. NA boosted its stake in Madrigal Pharmaceuticals by 53.2% in the third quarter. Glenmede Trust Co. NA now owns 1,567 shares of the biopharmaceutical company’s stock valued at $229,000 after acquiring an additional 544 shares during the last quarter. J.P. Morgan Private Wealth Advisors LLC purchased a new position in Madrigal Pharmaceuticals in the third quarter valued at about $314,000. Charles Schwab Investment Management Inc. grew its position in shares of Madrigal Pharmaceuticals by 11.3% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 109,501 shares of the biopharmaceutical company’s stock valued at $15,992,000 after acquiring an additional 11,083 shares during the period. Finally, Vanguard Group Inc. increased its stake in shares of Madrigal Pharmaceuticals by 7.4% during the 3rd quarter. Vanguard Group Inc. now owns 1,573,338 shares of the biopharmaceutical company’s stock worth $229,770,000 after purchasing an additional 107,816 shares during the last quarter. Institutional investors own 98.50% of the company’s stock. Madrigal Pharmaceuticals Stock Performance NASDAQ MDGL opened at $220.06 on Monday. The company’s 50 day simple moving average is $234.43 and its two-hundred day simple moving average is $221.25. The company has a debt-to-equity ratio of 0.14, a current ratio of 9.39 and a quick ratio of 9.39. Madrigal Pharmaceuticals, Inc. has a 1 year low of $119.76 and a 1 year high of $302.68. The stock has a market capitalization of $4.69 billion, a PE ratio of -9.53 and a beta of -0.33. Madrigal Pharmaceuticals (NASDAQ:MDGL – Get Free Report) last issued its quarterly earnings data on Tuesday, May 7th. The biopharmaceutical company reported ($7.38) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($6.06) by ($1.32). During the same period in the prior year, the firm posted ($4.23) earnings per share. Analysts predict that Madrigal Pharmaceuticals, Inc. will post -27.62 earnings per share for the current fiscal year. Wall Street Analyst Weigh In Several equities analysts have weighed in on the company. StockNews.com raised Madrigal Pharmaceuticals to a “sell” rating in a report on Friday, April 12th. B. Riley cut their price target on Madrigal Pharmaceuticals from $270.00 to $200.00 and set a “neutral” rating for the company in a research note on Friday, May 10th. TD Cowen boosted their price objective on Madrigal Pharmaceuticals from $349.00 to $390.00 and gave the company an “outperform” rating in a research note on Friday, March 15th. UBS Group increased their target price on shares of Madrigal Pharmaceuticals from $337.00 to $410.00 and gave the stock a “buy” rating in a research report on Friday, March 15th. Finally, Piper Sandler reiterated an “overweight” rating and issued a $336.00 target price on shares of Madrigal Pharmaceuticals in a research note on Thursday, March 14th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and nine have given a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $345.09. Read Our Latest Report on Madrigal Pharmaceuticals Insider Buying and Selling at Madrigal Pharmaceuticals In related news, Director Richard S. Levy sold 11,000 shares of the company’s stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $257.48, for a total value of $2,832,280.00. Following the transaction, the director now directly owns 10,298 shares in the company, valued at $2,651,529.04. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other news, CMO Rebecca Taub sold 2,676 shares of Madrigal Pharmaceuticals stock in a transaction on Monday, April 8th. The shares were sold at an average price of $245.99, for a total transaction of $658,269.24. Following the completion of the sale, the chief marketing officer now directly owns 458,999 shares of the company’s stock, valued at approximately $112,909,164.01. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Richard S. Levy sold 11,000 shares of the company’s stock in a transaction on Monday, April 1st. The stock was sold at an average price of $257.48, for a total transaction of $2,832,280.00. Following the completion of the transaction, the director now owns 10,298 shares of the company’s stock, valued at $2,651,529.04. The disclosure for this sale can be found here. Insiders have sold a total of 168,985 shares of company stock valued at $36,149,878 in the last 90 days. Corporate insiders own 23.92% of the company’s stock. Madrigal Pharmaceuticals Company Profile (Free Report) Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH.
  • 05/20/2024

Madrigal Pharmaceuticals (MDGL) Q1 2024 Earnings Call Transcript

  • Madrigal Pharmaceuticals (NASDAQ:MDGL ) Q1 2024 Results Conference Call May 7, 2024 8:00 AM ET Company Participants Tina Ventura - Chief IRO Bill Sibold - CEO Mardi Dier - CFO Conference Call Participants Yasmeen Rahimi - Piper Sandler Eli Merle - UBS Liisa Bayko - Evercore Jay Olson - Oppenheimer Ritu Baral - TD Cowen Thomas Smith - Leerink Partners Akash Tewari - Jefferies Jon Wolleben - Citizens Andrea Tan - Goldman Sachs Operator Good day, and thank you for standing by. Welcome to Madrigal Pharmaceuticals First Quarter 2024 Earnings Conference Call.
  • 05/07/2024

Madrigal Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates

  • CONSHOHOCKEN, Pa., May 07, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatitis (NASH), today reports first-quarter 2024 financial results and provides corporate updates.
  • 05/07/2024

Madrigal: Rezdiffra Launch Gets Underway, The Only Competition Is Off-Label

  • MDGL has launched Rezdiffra, the first drug approved for nonalcoholic steatohepatitis (NASH). Rezdiffra faces competition from potential off-label use of GLP-1RA drugs like semaglutide and tirzepatide, but there is potential for combination therapy too. Shortages of semaglutide and tirzepatide could help Rezdiffra's initial launch.
  • 04/30/2024

Madrigal Statement on the Passing of Dr. Stephen Harrison

  • CONSHOHOCKEN, Pa., April 24, 2024 (GLOBE NEWSWIRE) -- The Madrigal team is shocked and saddened to learn of the passing of Dr. Stephen Harrison.
  • 04/24/2024

Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

  • CONSHOHOCKEN, Pa., April 16, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced that the company granted equity awards to 7 new employees, in each case with a grant date of April 15, 2024, as equity inducement awards under the terms of the company's 2023 Inducement Plan. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
  • 04/16/2024

7 Stocks Analysts Are Loving Right Now (And You Should Too): April 2024

  • Many investors have one or more preferred fundamental or technical indicator. These help to cut through the noise surrounding a stock.
  • 04/15/2024

2 Under-the-Radar Growth Stocks to Consider

  • Madrigal Pharmaceuticals recently earned a groundbreaking therapy approval. Axsome Therapeutics is getting closer to transforming its lineup of medicines.
  • 04/10/2024

Better Booming Biotech Stock: Madrigal Pharmaceuticals vs. Viking Therapeutics

  • Madrigal Pharmaceuticals just commercialized its first medicine. Viking Therapeutics has a mid-stage candidate with great potential.
  • 04/05/2024

Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

  • CONSHOHOCKEN, Pa., April 03, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced that the company granted equity awards to 30 new employees, in each case with a grant date of April, 1 2024, as equity inducement awards under the terms of the company's 2023 Inducement Plan. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
  • 04/03/2024

1 No-Brainer Growth Stock to Buy Now

  • Madrigal Pharmaceuticals scored a historical regulatory approval last month. Even so, the market has been taking a cautious approach to Madrigal's shares.
  • 04/03/2024

The 3 Best Biotech Stocks to Buy in April 2024

  • Right now, biotech is one of the hottest sectors on the market, creating big opportunities for some of the best biotech stocks to buy in April. All of this is thanks to new innovation, millions of retiring baby boomers, demand for better care, pharmaceutical companies nearing patent expirations, a resurgence of mergers and acquisitions, and even new treatments that'll help you shed weight.
  • 04/01/2024

Better Buy: Viking Therapeutics vs. Madrigal Pharmaceuticals

  • Viking's drug candidate has shown promise in clinical studies as a potential weight loss medicine. Madrigal just launched the first (and so far only) medicine approved by the U.S. for NASH.
  • 03/29/2024

Is This Healthcare Stock a Screaming Buy After Scoring a Huge Drug Approval?

  • The Food and Drug Administration recently granted accelerated approval for Rezdiffra, a potential blockbuster for Madrigal Pharmaceuticals. At its peak, the drug could bring in more than $5 billion in revenue per year.
  • 03/29/2024

2 Top Biotech Buyout Candidates

  • After a strong resurgence in the back half of 2023 and continued momentum into the first quarter of 2024, biotech stocks are back in vogue. “Hawkish” Federal Reserve Policy, a brutal bear market in 2022, and investor preference for big tech stocks have meant underperformance for biotech stocks.
  • 03/28/2024

This Under-the-Radar Stock Just Hit a Major Milestone: Time to Buy?

  • Madrigal earned the first approval for a medicine in an area with a high unmet need. The commercial opportunity for this therapy, which treats a liver disease, looks exciting.
  • 03/22/2024

Is Madrigal Pharmaceuticals Stock a Better Buy Than Eli Lilly and Novo Nordisk After Its Huge FDA Win?

  • Last week's FDA approval of Rezdiffra in treating NASH is a huge milestone for Madrigal. Lilly and Novo Nordisk look much more impressive than Madrigal in most ways.
  • 03/19/2024

Madrigal Pharmaceuticals Announces Pricing of Upsized $600 Million Public Offering

  • CONSHOHOCKEN, Pa., March 18, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced the pricing of its underwritten public offering of 750,000 shares of its common stock at a public offering price of $260.0000 per share, and, to certain investors, pre-funded warrants to purchase 1,557,692 shares of common stock at a price of $259.9999 per pre-funded warrant, which represents the per share public offering price for the common stock less the $0.0001 per share exercise price for each such pre-funded warrant. The size of the offering was increased by $100 million subsequent to the initial announcement of the offering. The gross proceeds to Madrigal from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be approximately $600 million. Madrigal has granted the underwriters of the offering a 30-day option to purchase up to an additional 346,153 shares of common stock from the company at the public offering price, less underwriting discounts and commissions.
  • 03/18/2024

7 Biotech Stocks Ready to Ride the Sector's Resurgence

  • Why do you want to consider biotech stocks? Simply, the narrative comes down to numbers and a possible rotation.
  • 03/18/2024

Madrigal Pharmaceuticals Announces Proposed Public Offering

  • CONSHOHOCKEN, Pa., March 18, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced that it has commenced an underwritten public offering of $500 million in shares of its common stock and pre-funded warrants to purchase common stock. The purchase price of each pre-funded warrant will equal the price per share at which shares of common stock are being sold to the public in this offering, minus $0.0001, which will be the per share exercise price of each pre-funded warrant. Madrigal also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock offered in the public offering at the public offering price, less underwriting discounts and commissions. All of the shares in the proposed offering are to be sold by Madrigal.
  • 03/18/2024

Madrigal: Accelerated Rezdiffra Approval Puts It In The NASH Lead

  • On March 14, Madrigal Pharmaceuticals, Inc. announced that the FDA has granted accelerated approval for Rezdiffra, for the treatment of adults with noncirrhotic NASH with moderate to advanced liver fibrosis. This accelerated approval makes Rezdiffra the first and only FDA-approved NASH treatment, which will become available in April 2024 in the US. I discuss Madrigal Pharmaceutical as an investment opportunity in this article.
  • 03/18/2024

Madrigal Pharmaceuticals Wins Approval for the First Drug Targeting the Multibillion-Dollar NASH Market. Is the Stock a Screaming Buy?

  • Madrigal just won a milestone approval for Rezdiffra in treating NASH. NASH presents a massive potential market that could be worth tens of billions of dollars annually.
  • 03/17/2024

Biotech Stock Soars on FDA Drug Approval

  • Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) stock is taking off today, after the U.S. Food & Drug Administration (FDA) approved the biotech company's drug for the treatment of non-alcoholic steatohepatitis (NASH), a fatty liver disease.
  • 03/15/2024

Madrigal Pharmaceuticals wins FDA approval for liver disease drug; shares soar

  • Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) shares soared after the biopharmaceutical firm revealed its live disease drug Rezdiffra has won US Food and Drug Administration (FDA) approval.   Shares of the company gained 18.9% at about $290 in early trade on Friday.
  • 03/15/2024

Madrigal (MDGL) Stock Up as FDA Approves First Drug for NASH

  • Madrigal Pharmaceuticals' (MDGL) Rezdiffra (resmetirom) is the first and only medicine approved by the FDA for the treatment of NASH.
  • 03/15/2024

MDGL Stock Alert: The Historic Reason Madrigal Is Up 19% Today

  • Madrigal Pharmaceuticals (NASDAQ: MDGL ) stock is rising higher on Friday after the company got positive news from the Food and Drug Administration (FDA)! The big news here is the FDA granting accelerated approval for Rezdiffra as a treatment for adults with noncirrhotic nonalcoholic steatohepatitis (NASH) with moderate to advanced liver fibrosis.
  • 03/15/2024

FDA approves Madrigal Pharmaceuticals drug as first treatment for common NASH liver disease

  • The FDA's decision means Madrigal has succeeded in a disease area that several larger companies have failed — or are still trying to break into.
  • 03/14/2024

Madrigal Pharmaceuticals gets first FDA approval for drug targeting liver disease MASH

  • Madrigal Pharmaceuticals Inc. on Thursday received the first Food and Drug Administration approval for a drug designed to treat a severe liver disease known as MASH.
  • 03/14/2024

Missed Out on Eli Lilly? 3 Healthcare Stocks With Big Catalysts on the Horizon.

  • Madrigal Pharmaceuticals could be days away from winning its first FDA approval. Regeneron Pharmaceuticals expects several key regulatory decisions this year.
  • 03/09/2024

1 Wall Street Analyst Thinks Madrigal Pharmaceuticals Stock Is Going to $347. Is It a Buy Around $247?

  • Madrigal Pharmaceuticals may soon get its first regulatory approval. If it happens, it will become the first and only player in a large market.
  • 03/05/2024

1 Beaten-Down Stock That Could Soar by 40%, According to Wall Street

  • Madrigal Pharmaceuticals is close to a key regulatory approval that could send its stock price soaring. However, there are important issues with the company that savvy investors will consider.
  • 02/23/2024

Analysts see over 50% gains in these 2 mid-cap biotech stocks

  • In recent years, emergency Covid vaccines have ushered in several groundbreaking innovations that have changed the way drugs are developed and health care is administered. Advancements in the treatment of cancer, Alzheimer's disease and obesity have highlighted steady progress in the field.
  • 02/14/2024

Madrigal Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference

  • CONSHOHOCKEN, Pa., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), announced today that the Company will present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024 at 4:30 pm PT.
  • 01/03/2024

3 Biotech Bull Cases To Consider In 2024 - And 2 Wildcard Recommendations

  • The biotech sector is finishing 2023 on a high after a difficult couple of years, buoyed by Big Pharma M&A activity. The SPDR® S&P Biotech ETF has been soaring as a result of the M&A spree. Despite a challenging year, there have been some winners in the biotech sector - I have been fortunate to share a few successful tips with Seeking Alpha readers.
  • 12/29/2023

Huge Warren Buffett Purchase Highlights Hot Insider Buying

  • From executives to beneficial owners, insiders are increasingly stepping up to the buy window as we approach the end of the year.
  • 12/16/2023

These 2 Stocks Could Be About to Soar: Are They Buys?

  • Madrigal aims to offer a treatment in an area where success has eluded many peers. Bluebird Bio is closing in on its third U.S. approval for a gene-editing therapy.
  • 12/07/2023

The 3 Most Undervalued Biotech Stocks to Buy: November 2023

  • These companies in the biotechnology sector are doing incredible work and achieving wonderful developments. The result is not not only growth and profit for the companies, but they are also offering excellent and efficient solutions for the health of each one of us.
  • 11/14/2023

Madrigal Pharmaceuticals Bolstered By $500 Million Equity Infusion Is A 'Buy' Into 2024

  • Madrigal Pharmaceuticals is transitioning from clinical trials to market-ready solutions for non-alcoholic steatohepatitis (NASH) and liver fibrosis. Their leading candidate, Resmetirom, is in Phase III clinical trials and is expected to enter the market by spring 2024, pending FDA approval. A recent injection of $500 million in equity has strengthened Madrigal's financial position and supports a positive outlook for regulatory approval by 2024.
  • 11/05/2023

2 Risky Stocks With Massive Potential

  • Recursion Pharmaceuticals is looking to introduce a paradigm shift in the way biotechs develop drugs. Madrigal Pharmaceuticals developed a therapy for a disease that has eluded many of its larger peers.
  • 10/17/2023

Madrigal (MDGL) to Raise Capital Via Public Offering of $500M

  • Madrigal (MDGL) is raising funds through a public offering of 1.25 million shares of its common stock to use in commercial activities in the preparation of a potential launch of resmetirom in the United States.
  • 10/02/2023

Wall Street Thinks Madrigal Pharmaceuticals Could Climb 93%. Here's Why It Could Happen Soon.

  • Analysts have high hopes for Madrigal Pharmaceuticals over the coming year. Its drug resmetirom seems effective for a liver disease, non-alcoholic steatohepatitis.
  • 09/27/2023

Madrigal (MDGL) Gains on NDA for NASH Therapy Acceptance by FDA

  • Madrigal (MDGL) gains as new drug application for resmeritom to treat nonalcoholic steatohepatitis gets accepted by the FDA in the United States.
  • 09/14/2023

Madrigal Pharmaceuticals shares fall after new CEO named

  • Shares of Madrigal Pharmaceuticals Inc. MDGL, +2.91% fell more than 7% premarket on Monday after the company appointed Bill Sibold, a former Sanofi SNY, +1.06% executive, as its new CEO. Sibold succeeds Dr. Paul Friedman, the company's CEO since 2016, who will continue to serve on the board of directors, Madrigal said in a release.
  • 09/11/2023

The 3 Best Biotech Stocks to Buy Now: September 2023

  • Biotech stocks have underperformed in the U.S. stock market by a wide margin this year. The sector's most popular index, the iShares Biotechnology ETF (NASDAQ: IBB ), is down 5% since Jan. 27.
  • 09/04/2023

3 Biotech Stocks That Wall Street Analysts Can't Get Enough Of

  • This year has not been kind to biotech stocks, as the sector's most popular ETF, the iShares Biotechnology ETF (NASDAQ: IBB ), has fallen about 3% so far in 2023. Investors are probably worried about the impact of higher interest rates and potential reforms by Washington, DC on the sector.
  • 08/30/2023

The 3 Most Promising Pharma Stocks to Own Now

  • It is remarkable that day after day there are pharmaceutical companies working hard, researching and developing high-tech medicines for the improvement of human health and the treatment of severe diseases. These companies not only do a good job of researching and developing cures, but they also have an incredible financial performance.
  • 08/30/2023

Madrigal's Resmetirom Nears Commercialization Despite Market Concerns

  • Madrigal Pharmaceuticals is developing resmetirom, a drug for non-alcoholic steatohepatitis and fatty liver disease, with promising trial results. Madrigal has a strong cash position and manageable debt, but faces rising R&D costs and competition in the NASH therapeutics field. My recommendation remains a "Buy" for risk-tolerant investors, despite concerns about weight loss drugs reducing NASH market potential.
  • 08/20/2023

Madrigal: With Successful NASH Study, Possible Accelerated Approval Is Next

  • Madrigal Pharmaceuticals, Inc. dual surrogate Primary endpoint being met in phase 3 MAESTRO-NASH study allo